In-vivo efficiency of the novel azole compounds (ATTAF-1 and ATTAF-2) against systemic candidiasis in a murine model
Copyright © 2023 SFMM. Published by Elsevier Masson SAS. All rights reserved..
BACKGROUND: Antifungal resistance is the main health concern in the control of invasive fungal infections. This research was designed to further assess the antifungal activity of aryl-1,2,4-triazole-3-ylthio analogs of fluconazole (ATTAFs) against Candida albicans systemic candidiasis in the murine model.
MATERIALS & METHODS: The murine model of systemic candidiasis was designed via the inoculation of 1 × 106 CFU of Candida albicans. The treatment dosages of 3.5 and 35 mg/kg per day were selected for ATTAFs and fluconazole, respectively. The median survival time (MST) was assayed for 30 days post-infection. The quantitative and qualitative (via histopathology staining) fungal burden was also assessed. Furthermore, immunohistochemistry and biochemistry assays were performed to monitor anti-inflammatory activity using the Cyclooxygenase-2 (Cox-2) marker and changes in serum protein levels.
RESULTS: ATTAFs considerably improved the survival of the murine model (P < 0.003). Compared with fluconazole, the antifungal activity of ATTAFs and their MST showed no difference (P > 0.05). However, these compounds decreased the fungal burden in the kidneys, spleen, and liver.
CONCLUSION: Our research indicates that ATTAF-1 and ATTAF-2 are effective therapeutic agents due to their fungal clearing and increasing the MST in the murine model of systemic candidiasis. Although we concluded that these components are novel and promising candidates for the management of invasive candidiasis, further studies are warranted to correlate these findings with clinical outcomes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Journal de mycologie medicale - 33(2023), 4 vom: 18. Nov., Seite 101437 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fakhim, Hamed [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
8VZV102JFY |
|---|
| Anmerkungen: |
Date Completed 13.11.2023 Date Revised 15.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.mycmed.2023.101437 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362981574 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362981574 | ||
| 003 | DE-627 | ||
| 005 | 20240215231918.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.mycmed.2023.101437 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1294.xml |
| 035 | |a (DE-627)NLM362981574 | ||
| 035 | |a (NLM)37804566 | ||
| 035 | |a (PII)S1156-5233(23)00081-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fakhim, Hamed |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a In-vivo efficiency of the novel azole compounds (ATTAF-1 and ATTAF-2) against systemic candidiasis in a murine model |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.11.2023 | ||
| 500 | |a Date Revised 15.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 SFMM. Published by Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a BACKGROUND: Antifungal resistance is the main health concern in the control of invasive fungal infections. This research was designed to further assess the antifungal activity of aryl-1,2,4-triazole-3-ylthio analogs of fluconazole (ATTAFs) against Candida albicans systemic candidiasis in the murine model | ||
| 520 | |a MATERIALS & METHODS: The murine model of systemic candidiasis was designed via the inoculation of 1 × 106 CFU of Candida albicans. The treatment dosages of 3.5 and 35 mg/kg per day were selected for ATTAFs and fluconazole, respectively. The median survival time (MST) was assayed for 30 days post-infection. The quantitative and qualitative (via histopathology staining) fungal burden was also assessed. Furthermore, immunohistochemistry and biochemistry assays were performed to monitor anti-inflammatory activity using the Cyclooxygenase-2 (Cox-2) marker and changes in serum protein levels | ||
| 520 | |a RESULTS: ATTAFs considerably improved the survival of the murine model (P < 0.003). Compared with fluconazole, the antifungal activity of ATTAFs and their MST showed no difference (P > 0.05). However, these compounds decreased the fungal burden in the kidneys, spleen, and liver | ||
| 520 | |a CONCLUSION: Our research indicates that ATTAF-1 and ATTAF-2 are effective therapeutic agents due to their fungal clearing and increasing the MST in the murine model of systemic candidiasis. Although we concluded that these components are novel and promising candidates for the management of invasive candidiasis, further studies are warranted to correlate these findings with clinical outcomes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Candida albicans | |
| 650 | 4 | |a Murine model | |
| 650 | 4 | |a Systemic candidiasis | |
| 650 | 4 | |a Triazole derivatives | |
| 650 | 7 | |a Fluconazole |2 NLM | |
| 650 | 7 | |a 8VZV102JFY |2 NLM | |
| 650 | 7 | |a Antifungal Agents |2 NLM | |
| 650 | 7 | |a Azoles |2 NLM | |
| 700 | 1 | |a Vaezi, Afsane |e verfasserin |4 aut | |
| 700 | 1 | |a Morovati, Hamid |e verfasserin |4 aut | |
| 700 | 1 | |a Bandegani, Azadeh |e verfasserin |4 aut | |
| 700 | 1 | |a Abbasi, Kiana |e verfasserin |4 aut | |
| 700 | 1 | |a Emami, Saeed |e verfasserin |4 aut | |
| 700 | 1 | |a Nasiry, Davood |e verfasserin |4 aut | |
| 700 | 1 | |a Hashemi, Seyedeh Mahdieh |e verfasserin |4 aut | |
| 700 | 1 | |a Ahangarkani, Fatemeh |e verfasserin |4 aut | |
| 700 | 1 | |a Badali, Hamid |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal de mycologie medicale |d 1997 |g 33(2023), 4 vom: 18. Nov., Seite 101437 |w (DE-627)NLM093691998 |x 1773-0449 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2023 |g number:4 |g day:18 |g month:11 |g pages:101437 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.mycmed.2023.101437 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2023 |e 4 |b 18 |c 11 |h 101437 | ||